Icecure Medical Ltd. (ICCM)
NASDAQ:ICCM
Want to see ICCM full AI Analyst Report?
ICCM Stock Chart & Stats
$0.86
-$0.06(-4.41%)
At close: 4:00 PM EST
$0.86
-$0.06(-4.41%)
Day’s Range― - ―
52-Week Range$2.12 - $42.00
Previous CloseN/A
Volume318.06K
Average Volume (3M)5.35M
Market Cap
$15.16M
Enterprise Value$6.44M
Total Cash (Recent Filing)$8.12M
Total Debt (Recent Filing)$139.00K
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Aug 17, 2026EPS Estimate
-1.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.98
Shares Outstanding2,806,701
10 Day Avg. Volume15,907,880
30 Day Avg. Volume5,348,202
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)4.28
Price to Sales (P/S)11.48
P/FCF Ratio-2.65
Enterprise Value/Market Cap0.42
Enterprise Value/Revenue1.81
Enterprise Value/Gross Profit4.94
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$30.00Price Target Upside3388.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.96
Revenue Forecast (FY)$6.37M
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet With Very Low DebtVery low absolute debt and minimal leverage materially reduce near-term solvency risk and give management optionality to support commercialization or bridge financing. Over the next 2–6 months this provides flexibility to pursue U.S. scale-up, clinical studies, or targeted hiring without immediate refinancing pressure.
Regulatory Validation (FDA Clearance) Enabling U.S. Market AccessFDA clearance is a durable structural milestone that legitimizes ProSense® for clinicians, accelerates hospital adoption, and unlocks participation in post‑market studies. This sustains commercial momentum, supports payer conversations and international expansion efforts over multiple quarters as institutions evaluate adoption and training.
Expanding Installed Base Supports Recurring Consumable RevenueA growing installed base creates a durable revenue stream from single‑use cryoprobes and procedure consumables, which tends to be recurring and less volatile than capital sales. As system placements rise, follow‑on consumable demand can provide improving revenue visibility and leverage fixed commercial costs across more procedures.
Bears Say
High Cash Burn And Negative Operating Cash FlowTTM cash burn (~$15.3M) vastly exceeds current revenue, meaning the company cannot self‑fund growth and will likely need external capital. This is a persistent funding risk over the next several quarters and increases dilution or financing uncertainty unless commercial traction rapidly accelerates cash inflows.
Extremely Weak Profitability And Negative ReturnsVery wide negative margins and deeply negative ROE indicate the cost base is not aligned with current revenue scale. Sustained operating losses erode equity and constrain reinvestment capacity, meaning profitability improvement must be structural and multi‑quarter to materially reduce funding dependence.
Reimbursement Timing And UncertaintyDelayed physician CPT‑1 and conditional pass‑through payments create a structural headwind for physician office adoption and procedure economics. Without stable physician reimbursement, conversion of interest into broad system placements and higher‑volume outpatient procedures will be constrained for many quarters, limiting revenue scalability.
Icecure Medical News
ICCM FAQ
What was Icecure Medical Ltd.’s price range in the past 12 months?
Icecure Medical Ltd. lowest stock price was $2.12 and its highest was $42.00 in the past 12 months.
What is Icecure Medical Ltd.’s market cap?
Icecure Medical Ltd.’s market cap is $15.16M.
When is Icecure Medical Ltd.’s upcoming earnings report date?
Icecure Medical Ltd.’s upcoming earnings report date is Aug 17, 2026 which is in 56 days.
How were Icecure Medical Ltd.’s earnings last quarter?
Icecure Medical Ltd. released its earnings results on May 12, 2026. The company reported -$1.8 earnings per share for the quarter, missing the consensus estimate of -$1.4 by -$0.4.
Is Icecure Medical Ltd. overvalued?
According to Wall Street analysts Icecure Medical Ltd.’s price is currently Undervalued.
Does Icecure Medical Ltd. pay dividends?
Icecure Medical Ltd. does not currently pay dividends.
What is Icecure Medical Ltd.’s EPS estimate?
Icecure Medical Ltd.’s EPS estimate is -1.5.
How many shares outstanding does Icecure Medical Ltd. have?
Icecure Medical Ltd. has 2,806,701 shares outstanding.
What happened to Icecure Medical Ltd.’s price movement after its last earnings report?
Icecure Medical Ltd. reported an EPS of -$1.8 in its last earnings report, missing expectations of -$1.4. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Icecure Medical Ltd.?
Currently, no hedge funds are holding shares in ICCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Icecure Medical Ltd.
Headquartered in Caesarea, Israel, and founded in 2006, IceCure Medical Ltd is a medical device enterprise dedicated to inventing, refining, and marketing innovative solutions for treating human tumors through cryoablation, a freezing process. Their primary offering, the ProSense system, provides a specialized cryoablation therapy specifically for breast tumors.
ICCM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys strong positive momentum driven by 26% revenue growth, outsized North America (84%) and U.S. (31%) gains, FDA clearance, increasing active accounts (+46%), an approved 30‑site Choice post‑market study, and expanding commercial and clinical validation. Key near‑term risks include reimbursement timing (CPT‑1 and pass‑through uncertainty), limitations for office‑based reimbursement, and multi‑quarter conversion timelines for leads to system sales. On balance, the positives (regulatory milestone, accelerating sales, study approval and pipeline growth) outweigh the challenges, while some execution and reimbursement risks remain.View all ICCM earnings summariesICCM Stock 12 Month Forecast
Average Price Target
$30.00
▲(3388.37% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.44% Mutual Funds
― Other Institutional Investors
98.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---